Premium
Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes
Author(s) -
Satani K.,
Konya H.,
Hamaguchi T.,
Umehara A.,
Katsuno T.,
Ishikawa T.,
Kohri K.,
Hasegawa Y.,
Suehiro A.,
Kakishita E.,
Namba M.
Publication year - 2006
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2006.01849.x
Subject(s) - medicine , hepatocyte growth factor , diabetes mellitus , risk factor , pathophysiology , cardiology , type 2 diabetes , gastroenterology , endocrinology , receptor
Aims Recent studies have provided increasing evidence that hepatocyte growth factor (HGF) has a pathophysiological role in the development of diabetic complications. We set out to determine the relationship between serum HGF and risk factors for macroangiopathy including carotid atherosclerosis. Carotid atherosclerosis is an established and important risk factor for both cerebral and coronary artery diseases. Methods We studied 89 patients (48 males, 41 females, mean age 62.5 ± 10.3 years) with Type 2 diabetes (DM). Results Serum levels of HGF correlated positively with both intimal‐media thickness (IMT) ( r = 0.24, P = 0.0248) and plaque score ( r = 0.27, P = 0.0126). In multiple regression analysis, serum HGF was associated independently with IMT (standardized β = 0.28, P = 0.0499). We also found that both IMT and plaque score were higher in patients with ischaemic heart disease (IHD) than in patients without IHD, and that plaque score in patients with lacunar infarcts was higher than in patients without lacunar infarcts. Conclusions Serum HGF concentration may be a new marker of atherosclerotic complications in patients with Type 2 D M .